جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

20 مُخرَج نتائج البحث عن «Dopamine»

مقالوصول مفتوح20264استشهاد· Semantic Scholar

Synthesis, biological evaluation and in silico studies of novel propargyl-tethered isatin hydrazones as monoamine oxidase inhibitors for Parkinson’s disease

Scientific Reports · مجلد 16 (1)

Neurodegenerative disorders such as Parkinson’s disease are closely associated with dysregulated activity of monoamine oxidase-B (MAO-B), which leads to dopamine depletion and oxidative stress. Despite the availability of numerous monoamine oxidase (MAO) inhibitors on the market, their irreversibility and associated side effects necessitate the development of more effective and reversible MAO-B inhibitors. In this study, a series of twenty-one indole-based derivatives (PSH1 - PSH21) , collectively designated as PSH , was synthesised and evaluated for inhibitory activity against MAO isoforms. Most synthesised compounds showed higher inhibitory activity toward MAO-B than MAO-A, indicating selectivity for MAO-B. Among the PSH derivatives, PSH18 exhibited the most potent MAO-B inhibitory activity (IC 50 = 0.95 ± 0.02 µM), followed by PSH6 ( IC 50 = 1.79 ± 0.40 µM) and PSH2 (IC 50 = 1.96 ± 0.08 µM). Compound PSH18 showed the highest selectivity index value of 42.11, followed by PSH6 (22.35) and PSH2 (20.41). Additionally, PSH18 was confirmed to be a competitive and reversible inhibitor of MAO-B with an inhibition constant value of 0.89 ± 0.035 µM. Notably, PSH18 exhibited good permeability across the blood–brain barrier in parallel artificial membrane permeability assay experiments, along with acceptable absorption, distribution, metabolism, excretion, and toxicity parameters predicted through in silico modelling, suggesting its potential as a central nervous system-targeted molecule. Molecular docking and a 200 ns molecular dynamics simulation demonstrated stable binding of the ligand to the MAO-B active-site pocket, driven by hydrophobic and π–π stacking interactions with key amino acid residues lining the aromatic cage. Moreover, the calculated binding energy indicated strong ligand–protein interactions. Overall, these results indicate that the PSH scaffold could serve as a promising lead structure for the development of potent and selective MAO-B inhibitors. These compounds may have therapeutic potential for the treatment of neurodegenerative diseases.

monoamine oxidase B inhibitorsParkinson's diseaseblood-brain barrier permeabilityADME prediction
مقالوصول مفتوح2026

Tavapadon in Parkinson’s disease: D1/D5 receptor pharmacology, clinical evidence, and translational perspectives

Frontiers in Aging Neuroscience · مجلد 18

Tavapadon is an oral, once-daily, non-catechol partial agonist selective for the D1 and D5 dopamine receptors and represents a mechanistically distinct option currently under clinical investigation for Parkinson disease (PD). This narrative review critically evaluates the biological rationale for D1/D5 receptor targeting, the pharmacological and preclinical development of tavapadon, and the accumulating phase 1–3 clinical evidence for its use as monotherapy in early PD and as adjunctive therapy in patients with motor fluctuations, while highlighting remaining evidence gaps and methodological limitations. A non-systematic literature search of PubMed/MEDLINE, Embase, ClinicalTrials.gov , and Scopus (through May 2026) was performed to identify representative and pivotal randomized controlled trials, pharmacokinetic/pharmacodynamic studies, and mechanistic preclinical investigations relevant to tavapadon and D1/D5 receptor agonism; this narrative approach was not intended to be exhaustive or fully reproducible in the manner of a systematic review. Mechanistically, selective stimulation of the direct striatal pathway together with submaximal intrinsic efficacy at the D1 receptor has been proposed, as a mechanistic hypothesis rather than a demonstrated clinical mechanism, to preserve antiparkinsonian benefit while limiting the receptor-signaling intensity implicated in levodopa-induced dyskinesia. In the phase 2 PARKWAY-II study and the now fully published phase 3 TEMPO-1 and TEMPO-2 trials, fixed- and flexible-dose tavapadon produced clinically meaningful improvements in MDS-UPDRS motor scores compared with placebo in early PD, and in the phase 3 TEMPO-3 trial, adjunctive tavapadon significantly increased daily good ON time and reduced OFF time in levodopa-treated patients with motor fluctuations; efficacy in all trials has been demonstrated only against placebo, with no head-to-head data against levodopa or other dopamine agonists. Adverse events were more frequent with tavapadon than placebo (approximately 72–76% versus 55% across TEMPO-2 and TEMPO-3), with nausea, headache, and dizziness the most common; no excess signal of impulse-control disorders relative to placebo was detected over the available 26–27-week controlled treatment period, and no clinically significant QTc prolongation was observed. The 58-week open-label TEMPO-4 extension, now reported in a peer-reviewed AAN abstract publication in Neurology alongside earlier interim conference data, suggests sustained benefit and a stable long-term levodopa requirement, but lacks a randomized control and cannot yet establish long-term safety superiority over existing agents. Tavapadon is a mechanistically novel candidate with preliminary evidence of efficacy; its ultimate clinical utility will depend on head-to-head trials and long-term safety data.

Parkinson's diseasedopamine D1 receptordopamine D5 receptormotor fluctuations
مقالمفتوح (مستودع)20255استشهاد· Semantic Scholar

Combatting BPA‐Induced Neurotoxicity With Purple Carrot Extract ( Daucus carota ): Modulation of Key Neurotransmitters and Cellular Pathways in Albino Rats

Journal of Food Biochemistry · مجلد 2025 (1)

Ethnopharmacological Relevance: Bisphenol A (BPA) is a widely used chemical, particularly in producing epoxy resins and polycarbonate plastics, which can contaminate food and water sources. Even low levels of BPA exposure have been associated with negative impacts on neural development, leading to neurotoxicity. Purple carrots, known for their health‐promoting properties, are rich in bioactive compounds such as polyphenols. Materials and Methods: This study aimed to evaluate the neuroprotective effects of purple carrot extract in mitigating BPA‐induced neurotoxicity in albino rats. Forty albino rats were divided into four groups: Group I (control) received water and a standard diet. Group II (BPA group) was orally administered 50 mg/kg body weight of BPA dissolved in 1 mL of olive oil daily for 30 days. Group III received 400 mg/kg of purple carrot extract along with 50 mg/kg of BPA daily. Group IV received 800 mg/kg of purple carrot extract along with 50 mg/kg of BPA daily, following the same 30‐day oral administration protocol. Results: The results showed that treatment with purple carrot extract increased serum levels of critical neurotransmitters, including serotonin, dopamine, acetylcholine, acetylcholineesterase, and gamma‐aminobutyric acid (GABA). Additionally, brain tissue analysis revealed elevated activity of antioxidant enzymes, such as catalase (CAT) and superoxide dismutase (SOD), in response to extract administration. Conversely, the extract significantly reduced levels of malondialdehyde (MDA), α‐tumor necrosis factor (α‐TNF), and interleukin‐6 (IL‐6) in brain tissues compared to the BPA‐only group. These results indicate that purple carrot extract regulates genes related to oxidative stress, inflammation, and apoptosis in a dose‐dependent manner during BPA‐induced neurotoxicity. At a dose of 400 mg/kg, the extract increased the expression of antioxidant genes like Nrf2 and HO‐1 while reducing the pro‐apoptotic marker Bax. At the higher dose of 800 mg/kg, these protective effects were even more pronounced, leading to enhanced neuroprotection through increased antioxidant and antiapoptotic gene expression and reduced inflammation, mainly through the MAPK pathway. Conclusion: The study demonstrates that purple carrot extract reduces BPA‐induced neurotoxicity in rats by enhancing antioxidants, neurotransmitters, and anti‐inflammatory responses, suggesting natural protection against BPA‐related neural damage.

bisphenol Aneurotoxicitycarrotneuroprotection
مقالوصول مفتوح20253استشهاد· Semantic Scholar

A novel nanocomposite Lf-DA-MSN-PF127 aided the delivery of dopamine for the treatment of Parkinson's disease in a rat model

Nanoscale Advances · مجلد 7 (19) · 6017-6031

experiments using a rotenone (ROT) induced PD rat model confirmed that Lf-DA-MSN-PF127 crosses the BBB and delivers dopamine. It remarkably boosts motor symptoms and dopamine levels in ROT-induced PD rats. Our study illustrates the nontoxic effect of the Lf-DA-MSN-PF127 nanocomposite and its efficacy in delivering dopamine across the BBB, providing a novel treatment strategy for PD.

Parkinson's diseasenanocompositesmesoporous silica nanoparticlesblood-brain barrier penetration
مقالوصول مغلق202413استشهاد· Semantic Scholar

Hesperetin protects against rotenone-induced motor disability and neurotoxicity via the regulation of SIRT1/NLRP3 signaling

Toxicology Mechanisms and Methods · مجلد 34 (9) · 1045-1060

Rotenone is a pesticide that causes complex I inhibition and is widely known to induce motor disability and experimental Parkinson’s disease (PD) in rodents. Evidence suggests a crucial role for sirtuin/nuclear factor-kappaB/nod-like receptor family, pyrin domain-containing 3 (SIRT1/NFκB/NLRP3) signaling and inflammation in PD and rotenone neurotoxicity. Hesperetin (C16H14O6) is a citrus flavonoid with documented anti-inflammatory activity. We investigated the value of hesperetin in delaying rotenone-induced PD in mice and the possible modulation of inflammatory burden. PD was induced in mice via rotenone injections. Groups were assigned as a vehicle, PD, or PD + hesperetin (50 or 100 mg/kg) and compared for the motor function, protein level (by ELISA), and gene expression (by real-time PCR) of the target proteins, histopathology, and immunohistochemistry for tyrosine hydroxylase enzyme. Hesperetin (50 or 100 mg/kg) alleviated the motor disability and the striatal dopamine level and decreased the expression of NLRP3 and NF-κB but increased SIRT1 expression (p < 0.05). Further, it enhanced the neural viability and significantly decreased neural degeneration in the substantia nigra, hippocampus, and cerebral cortex (p < 0.05). Taken together, we propose that hesperetin mediates its neuroprotective function via alleviating modulation of the SIRT1/NFκB/NLRP3 pathway. Therefore, hesperetin might delay the PD progression.

hesperetinrotenoneParkinson's diseaseneuroprotection
مقالوصول مفتوح20243استشهاد· Semantic Scholar

Comparison of Efficacy and Safety of Device-Based Interventions Versus Pharmacological Therapy in the Management of Patients With Advanced Parkinson’s Disease: A Literature Review

Cureus · مجلد 16 (12) · e76044-e76044

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms that profoundly impact patients' quality of life. While pharmacological therapies such as levodopa remain the mainstay of treatment, their long-term use is often limited by motor complications. Device-based interventions, including deep brain stimulation (DBS) and continuous dopaminergic infusions, have emerged as alternatives, promising sustained symptomatic control and reduced medication-related side effects. This systematic review and meta-analysis evaluate the comparative efficacy, safety, and cost-effectiveness of device-based interventions versus pharmacological therapies in the management of advanced PD. A comprehensive search was conducted across multiple databases to identify randomized controlled trials, observational studies, and systematic reviews. Primary outcomes included motor function improvement, quality of life, and adverse events. Meta-analyses were performed, and subgroup analyses explored the effectiveness of specific interventions. Device-based interventions demonstrated superior efficacy over pharmacological therapies, with a pooled effect size (Cohen's d) of 1.12 (95% confidence interval (CI): 0.94-1.29) for motor symptom control and quality of life improvements. Subgroup analyses showed DBS and levodopa-carbidopa intestinal gel to be particularly effective, with levodopa-carbidopa intestinal gel showing a Cohen's d of 1.25 (95% CI: 0.91-1.58). Device-based therapies also reduced medication dosages and associated motor complications. Sensitivity analyses confirmed the robustness of these findings, and no significant publication bias was detected. However, gaps remain in understanding the long-term outcomes and cost-effectiveness of these interventions. Device-based interventions, especially DBS and levodopa-carbidopa intestinal gel, offer superior symptom control and quality of life improvements compared to traditional pharmacological therapies in advanced PD. These findings support the integration of device-based therapies into personalized treatment strategies. Further research is needed to explore long-term outcomes and establish standardized guidelines for their implementation in clinical practice.

advanced Parkinson's diseasedeep brain stimulationlevodopa-carbidopa intestinal gellevodopa
مراجعةوصول مفتوح202328استشهاد· Semantic Scholar

Piperidine: A Versatile Heterocyclic Ring for Developing Monoamine Oxidase Inhibitors

ACS Omega · مجلد 8 (41) · 37731-37751

The monoamine oxidase enzyme (MAO), which is bound on the membrane of mitochondria, catalyzes the oxidative deamination of endogenous and exogenous monoamines, including monoamine neurotransmitters such as serotonin, adrenaline, and dopamine. These enzymes have been proven to play a significant role in neurodegeneration; thus, they have recently been researched as prospective therapeutic targets for neurodegenerative illness treatment and management. MAO inhibitors have already been marketed as neurodegeneration illness treatments despite their substantial side effects. Hence, researchers are concentrating on developing novel molecules with selective and reversible inhibitory properties. Piperine, which is a phytochemical component present in black pepper, has been established as a potent MAO inhibitor. Piperine encompasses a piperidine nucleus with antibacterial, anti-inflammatory, antihypertensive, anticonvulsant, antimalarial, antiviral, and anticancer properties. The current Review focuses on the structural changes and structure-activity relationships of piperidine derivatives as MAO inhibitors.

piperidine derivativesmonoamine oxidase inhibitorspiperinestructure-activity relationship
مقالوصول مفتوح202315استشهاد· Semantic Scholar

Hesperidin Attenuates Titanium Dioxide Nanoparticle-Induced Neurotoxicity in Rats by Regulating Nrf-2/TNF-α Signaling Pathway, the Suppression of Oxidative Stress, and Inflammation

ACS Omega · مجلد 8 (40) · 37584-37591

High Resolution Image Download MS PowerPoint Slide Background: Titanium dioxide nanoparticles (TiO 2 NPs) are widely utilized and consumed mainly as food additives. Oxidative stress is considered to be the basic effect of TiO 2 NPs through biological interactions. Hesperidin (HSP) is a bioflavonoid (flavanone glycoside) with lipid-lowering, inflammation, oxidative stress suppression, antihypertensive, cancer-fighting, and antiedema effects. Objective: This study was to investigate the possible protective influences of HSP of subchronic oral TiO 2 NP exposure on the brains of rats, including neurotransmitters, oxidative stress/antioxidant parameters, inflammatory markers, and histological changes in the brains of adult male albino rats. Methodology: The experiment was executed on 80 albino rats. The animals were randomly divided into 4 equal groups. The first group served as a control; the second group was treated with oral doses of HSP (100 mg/kg Bw daily); the third group received TiO 2 NPs (200 mg/kg Bw orally daily); and the fourth group was treated with TiO 2 NPs and an oral dose of HSP daily for 8 weeks. Blood samples were obtained for biochemical analysis. Neurotransmitters, oxidative stress biomarker levels, and inflammatory markers were measured in brain homogenates. Histological examination of the brain was performed through H&E staining. Results: Coadministration of hesperidin with TiO 2 NPs orally for 8 weeks decreased the levels of MDA, TNF-α, AChE, and dopamine in brain homogenates, which were increased in the TiO 2 NP group. It increased the other oxidative biomarkers (SOD, CAT, and GPx) and Nrf-2 expression levels. Brain histological sections of the TiO 2 NP-treated group show degeneration, necrosis, congestion, and inflammatory cell infiltration that decreased markedly in the coadministration of hesperidin with the TiO 2 NP group. Conclusion: Hesperidin cotreatment offers significant protection against TiO 2 NP-induced oxidative stress and biochemical and histological alteration in the brain.

hesperidintitanium dioxide nanoparticlesnanoparticle neurotoxicityoxidative stress
مراجعةوصول مفتوح20232استشهاد· Semantic Scholar

Pharmacological Management for Pediatric Irritable Bowel Syndrome: A Review

Cureus · مجلد 15 (11) · e49197-e49197

Irritable bowel syndrome is a multifactorial disease with chronic symptoms that interfere with the quality of life of patients. It represents one of the most common causes of functional abdominal pain in the pediatric population. Various theses with little evidence tried to explain the pathophysiology of the disease. Neurological origin was one of the theories explaining the disease, either by the disturbance of neurotransmitters like dopamine, noradrenaline, and serotonin, which have some evidence of their relation to GI tract functions. Other factors like bio-psycho-social factors that affect the pediatric population are represented in bullying, unrealistic academic expectations from the parents, continuous educational stress, and difficult relationships with peers. Other factors may be genetic abnormalities of the receptors or visceral hypersensitivity. Treatment strategies for the disease varied from physical activity like yoga to a diet like a low-FODMAP diet. Pharmacological treatment of the disease targets the presenting symptoms, represented by antispasmodic drugs treating abdominal pain/discomfort, antipsychotics that regulate the disturbance in the brain-gut axis, and other drugs targeting diarrhea or constipation that present with the patient according to the type of IBS and the condition of the patient.

pediatric irritable bowel syndromepharmacotherapyfunctional abdominal paingut-brain axis
مقالوصول مفتوح202261استشهاد· Semantic Scholar

Celastrol and thymoquinone alleviate aluminum chloride-induced neurotoxicity: Behavioral psychomotor performance, neurotransmitter level, oxidative-inflammatory markers, and BDNF expression in rat brain

Biomedicine & Pharmacotherapy · مجلد 151 · 113072-113072

Exposure to aluminum chloride (AlCl3) induces progressive multiregional neurodegeneration in animal models by promoting oxidative stress and neuroinflammation. The current study was designed to assess the potential efficacy of the natural antioxidants celastrol and thymoquinone (TQ) for alleviating AlCl3-induced psychomotor abnormalities and oxidative-inflammatory burden in male albino rats. Four treatment groups were compared: (i) a vehicle control group, (ii) a AlCL3 group receiving daily intraperitoneal (i.p.) injection of AlCl3 (10 mg/kg) for 6 weeks, (iii) a AlCl3 plus TQ (10 mg/kg, i.p.) cotreatment group, and (iv) a AlCl3 plus celastrol (1 mg/kg, i.p.) cotreatment group. Open-field, rotarod, and forced swimming tests were conducted to assess locomotor activity, motor coordination, anxiety-like behavior, and depressive-like behavior. Acetylcholine (ACh), dopamine, and serotonin levels were measured in brain homogenates. Malondialdehyde (MDA), total antioxidant capacity (TAC), and catalase activity were measured as oxidative stress markers, while tumor necrosis factor-α (TNF-α) and interlukin-6 (IL-6) expression levels were measured as inflammatory markers. Brain derived neurotrophic factor (BDNF) mRNA was measured as an index for the endogenous neuroprotective response. Daily AlCl3 injection reduced free ambulation, impaired motor coordination, promoted anxiety- and depression-like behaviors, reduced whole-brain ACh, dopamine, and serotonin concentrations, increased MDA accumulation, reduced TAC, elevated TNF-α and IL-6, and suppressed BDNF mRNA expression. All of these effects were significantly reversed by TQ or celastrol cotreatment. Thus, TQ and celastrol may be promising treatments for AlCl3-induced neurotoxicity as well as neurodegenerative diseases involving oxidative stress and neuroinflammation.

aluminum chloride-induced neurotoxicitycelastrolthymoquinoneoxidative stress
مراجعةوصول مفتوح202244استشهاد· Semantic Scholar

Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence

Frontiers in Pharmacology · مجلد 13 · 805388-805388

Parkinson's disease (PD) is the second leading neurodegenerative disease that is characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been considered a mainstay for the management of PD; however, its prolonged treatment is often associated with abnormal involuntary movements and results in L-DOPA-induced dyskinesia (LID). Although LID is encountered after chronic administration of L-DOPA, the appearance of dyskinesia after weeks or months of the L-DOPA treatment has complicated our understanding of its pathogenesis. Pathophysiology of LID is mainly associated with alteration of direct and indirect pathways of the cortico-basal ganglia-thalamic loop, which regulates normal fine motor movements. Hypersensitivity of dopamine receptors has been involved in the development of LID; moreover, these symptoms are worsened by concurrent non-dopaminergic innervations including glutamatergic, serotonergic, and peptidergic neurotransmission. The present study is focused on discussing the recent updates in molecular mechanisms and therapeutic approaches for the effective management of LID in PD patients.

levodopa-induced dyskinesiaParkinson's diseaselevodopadopamine receptor hypersensitivity
مقالوصول مغلق20222استشهاد· Semantic Scholar

Plumbagin Attenuates Depression-Like Behavior in Mice by Modulating Dopamine Levels

Current Topics in Nutraceutical Research · مجلد 20M (1) · M6-M10

This research was done to investigate the antidepressant properties of plumbagin using a chronic mild stress induced depression model in experimental animals. Albino mice of either sex were given 3 weeks of chronic mild stress and their antidepressant properties were assessed using the tail suspension test and sucrose preference test. The period of immobility in the tail suspension test and the percentage preference for sucrose solution were both recorded and compared. Plumbagin was given in three doses (4, 8, and 16 mg/kg). The immobility time in the tail suspension test was significantly decreased in the animals that received plumbagin administration during the three phases of the chronic mild stress when compared to control. Further, plumbagin administration dose dependently increased the percentage preference for sucrose solution on par with the standard antidepressant, imipramine. The spontaneous locomotion count was significantly higher in the animals that received a high dose of plumbagin. Further, a high dose of plumbagin significantly reverses the chronic mild stress induced plasma corticosterone and nitrile levels. Additionally, a high level of dopamine was found in the prefrontal and nucleus accumbens parts of the brain. To summarize, plumbagin, in addition to its antioxidant characteristics, has potential antidepressant action at high doses, potentially by raising the dopamine levels.

plumbaginantidepressant effectsdepression-like behaviorchronic mild stress
مقالوصول مفتوح2022

Classification, pathophysiology and principle of therapy of shock

International Journal of Community Medicine and Public Health · مجلد 9 (9) · 3613-3613

Shock is a clinical syndrome that results from lack of oxygen utilization or supply to vital organs resulting in hypoxia. Shock is associated with significant morbidity and mortality as if not treated timely can lead to multiple organ failure and death. The mortality rate of shock ranges from 20% to 50%. Shock has several pathophysiologies including intracardiac etiologies such as myocardial infarction, myopathy, or severe arrhythmia which produce altered maturation and cause heart failure while loss of internal or external fluid due to trauma or bleeding often results in hypovolemia. Also, obstruction by extracardiac causes and activation of inflammatory cascade can induce shock. The purpose of this research is to review the available information about the classification, pathophysiology and principle of therapy of shock. The major classification of shock includes cardiogenic, hypovolemic, obstructive and distributive shock. Distributive shock is further divided into three subclasses of septic, anaphylactic and neurogenic shock. Haemorrhagic shock is also the sub-type of hypovolemic shock. Each class of shock requires a specific treatment and timely management to prevent any further complications. Constant examination, resuscitation and re-evaluation are important in therapy of shock. To treat hypotension and to increase cardiac output, vasopressor drugs and inotropic adrenergic drugs continue to be the most widely used therapies. Endogenous catecholamines such as epinephrine, norepinephrine, and dopamine among other vasopressors have been shown to be effective in treating various types of shocks that are controlled as part of treatment for shock. Early diagnosis and prompt treatment can help in prevention of complications of shock also enhancing the recovery of patients.

shockshock classificationcardiogenic shockhypovolemic shock